NasdaqGM - Delayed Quote USD

TriSalus Life Sciences, Inc. (TLSIW)

1.4000
+0.0200
+(1.45%)
As of May 15 at 4:00:00 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Mary T. Szela B.S.N., M.B.A. CEO, President & Director 624.04k -- 1964
Ms. Jodi Devlin Chief of Clinical Strategy & Operations 651.72k -- 1963
Mr. James E. Young CFO, Secretary & Treasurer -- -- 1962
Ms. Lori Ann Santamaria Vice President of Operations -- -- --
Ms. Jennifer L. Stevens J.D. Chief Regulatory Officer 630k -- 1962
Dr. Richard B. Marshak M.B.A., MBA, VMD Chief Commercial Officer -- -- 1959
Dr. Bryan F. Cox Ph.D. Chief of Research -- -- 1962

TriSalus Life Sciences, Inc.

6272 West 91st Avenue
Westminster, CO 80031
United States
(888) 321-5212 https://trisaluslifesci.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
110

Description

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Corporate Governance

TriSalus Life Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events